Nauset Wealth Management’s VanEck Biotech ETF BBH Stock Holding History

Nauset Wealth Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$166K	Buy	+1,023	New	+$166K	0.13%	61

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

Nauset Wealth Management's BBH Position: Q1 2022 in Review

Nauset Wealth Management opened a new position in VanEck Biotech ETF (BBH) in Q1 2022: 1,023 shares worth $166K. The stake represents 0.13% of the portfolio and ranks #61 among its holdings.

115 funds tracked by Wall St. Rank hold BBH as of Q1 2022.

Nauset Wealth Management held 1,023 shares of VanEck Biotech ETF worth $166K as of Q1 2022.
VanEck Biotech ETF was a new Nauset Wealth Management position in Q1 2022.
VanEck Biotech ETF made up 0.13% of Nauset Wealth Management's portfolio in Q1 2022, its #61 holding.
115 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2022.

Based on Nauset Wealth Management's 13F filing for Q1 2022, filed 28 Apr 2022.